Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data
Lexicon Pharmaceuticals (LXRX) reported Q3 2026 revenues of $11.3M, including a $10M milestone from Novo Nordisk. Key updates: Phase 3 Sonata HCM trial data expected Q1 2027, LX-9851 program advancing, and positive preclinical obesity data for pilavapidin. Net loss was $14.0M, or $0.03 per share, with $183.2M in cash. The company highlighted upcoming milestones, including the Sonata HCM data readout and Zynquista NDA resubmission in Q1 2027.
How this was made

The 30-second read
Why it matters
Earnings miss may trigger a sell‑off, but pipeline milestones could attract speculative buying ahead of Phase 3 data.
Market read
Primary earnings disclosure with modest financials and pipeline updates; relevant for biotech traders monitoring upcoming data releases.
What to watch
Potential upside from partnership with Novo Nordisk and the obesity preclinical data may be undervalued.
Background
Lexicon Pharmaceuticals held its Q3 2026 earnings call, providing financial results and updates on multiple pipeline programs.
Ticker impact
Lexicon reported Q3 2026 results with $11.3M revenue, $14M net loss and a $10M milestone from Novo Nordisk, plus upcoming Phase 3 data.
likely downward pressure as market prices in the net loss and higher expenses
The disclosed loss and higher SG&A outweigh the modest revenue, while the milestone is a small positive offset.
Market effects
Highlights ongoing activity in the rare‑disease biotech sector and potential interest in SGLT1/2 inhibitors for HCM.
Limited to US biotech investors; no broader regional effect.
Modest, confined to niche therapeutic areas and partner Novo Nordisk.
Counterpoint
The $10M milestone and upcoming Phase 3 readout could spark a short‑cover rally if the data exceed expectations.
Key entities
- CompanyLexicon Pharmaceuticals Inc
US‑listed biotech reporting Q3 2026 earnings.
- PartnerNovo Nordisk
Provided a $10M milestone payment for the LX‑9851 program.



